Enterprise Value to EBITDA Ratio: XBiotech USA (XBIT)
This price chart shows that XBiotech Inc. (XBIT) is trading at an EV/EBITDA multiple of 0.00. The company's antibody synthesis production facilities are operating seamlessly and adhering to maintenance schedules. Business success relies on the confirmed efficacy of drugs in final-stage trials and patent protection. Ownership of an innovative base allows for the systematic creation of new anti-inflammatory drugs, ensuring long-term revenue.
xbiotech.com - analytical breakdowns and key metrics (XBIT)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
XBIT - Profit After Payment of Taxes|Projected Future Earnings XBiotech Inc.|XBIT - Market Cap to Earnings|Forward P/E Multiple XBiotech|XBIT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple XBIT|XBIT - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months XBiotech|XBIT - Earnings per share for the trailing year|Quarterly EPS earnings growth xbiotech.com|XBIT - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year XBiotech Inc.
Summary company analytics:XBiotech USA XBIT
To identify fundamentally resilient assets, investors utilize EV/EBITDA, which compares a company's enterprise value, including debt, with its operating profit before taxes. By analyzing the EV/EBITDA trend of the heavy business segment, one can assess how the proprietary bio-factories of XBiotech Inc. (XBIT) and its control over raw materials transform high margins into actual enterprise value while mitigating debt load risks.
Analysis of competing companies
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|delcath.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Candel - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Accuray, Inc. ARAY|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA actuatetherapeutics.com (ACTU)|Enterprise Value to EBITDA Ratio CTOR|HURA (TuHURA) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple TARA|FATE - Company Value to EBITDA|EV/EBITDA Multiple WHWK (Aadi Bioscience)|TCRX - Enterprise Value to EBITDA Ratio|Champions Oncology Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CVM (CEL-SCI Corporation)|OSTX (OS Therapies Inc) - Enterprise Value to EBITDA Ratio|Radiopharm Theranostics Ltd - Business Value to Operating Income Before Depreciation|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Adlai Nortye Limited (ANL) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|Tempest Therapeutics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|MURA: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Kairos Pharma Ltd KAPA|OKUR (onkuretherapeutics.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation GDTC|CRIS (Curis Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APLM|EV/EBITDA Multiple THAR|Total Company Value to Operating Income Before Depreciation Ratio advanbiomed.com|Genprex - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio CLDI (Calidi Biotherapeutics Inc.)|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|SLRX: EV/EBITDA Multiple|purple-biotech.com (PPBT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|Enterprise Value to Operating Income Before Depreciation BGNE (BeiGene Ltd.)|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|EV/EBITDA Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Company Value to EBITDA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
